(Q37856310)

24 August 2017

1 reference

title

Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics (English)

1 reference

24 August 2017

0 references

Tomomi Masuda

1

1 reference

24 August 2017

Eiji Miyoshi

series ordinal

2

1 reference

24 August 2017

publication date

24 March 2011

1 reference

Clinical Chemistry and Laboratory Medicine

24 August 2017

published in

1 reference

24 August 2017

volume

49

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

959-966

1 reference

Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Biological function of fucosylation in cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Hepatocellular carcinoma: recent trends in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

The global health burden of infection-associated cancers in the year 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Risk of HCC: genetic heterogeneity and complex genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Molecular viral oncology of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Risk factors for hepatocellular carcinoma in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Diagnosis and Treatment of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Management of hepatitis B: 2000--summary of a workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Hepatocellular carcinoma--what's new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Screening for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Carbohydrate-based measurements on alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Purification and cDNA cloning of porcine brain GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha1-->6fucosyltransferase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

GP73, a novel Golgi-localized protein upregulated by viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Cycling of early Golgi proteins via the cell surface and endosomes upon lumenal pH disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

N-linked glycosylation of the liver cancer biomarker GP73

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Expression of OCI-5/glypican 3 during intestinal morphogenesis: regulation by cell shape in intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Glypican-3 is overexpressed in human hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Expressions of HSP70 and HSP27 in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Heat shock proteins in pancreatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Heat shock proteins in renal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Regulation of heat shock protein 70 gene expression by c-myc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Specific interaction between the p53 cellular tumour antigen and major heat shock proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Early HCC: diagnosis and molecular markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Proteomics and liver fibrosis: identifying markers of fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Noninvasive measures of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Identification of N-glycan serum markers associated with hepatocellular carcinoma from mass spectrometry data

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.152

21 January 2018

Identifiers

DOI

10.1515/CCLM.2011.152

1 reference

24 August 2017

1 reference